Stay updated with breaking news from Biocon Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biocon stock ended 2.05% higher at Rs 276.50 on Thursday against the previous close of Rs 270.95 on BSE. The stock touched an intraday high of Rs 277.60 .
The Nifty Pharma index was trading 0.28 per cent down at 18949.9.
The Nifty Pharma index closed 0.32 per cent up at 19003.15.
The agreement licenses the company to launch in the US in February 2025, once approved by the US Food and Drug Administration(USFDA), Biocon Biologics said in a statement.
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that the Company has signed a settlement and license agreement with Janssen Biotech Inc., and Johnson & Johnson (collectively known as Janssen) that clears the way to commercialize its Bmab 1200, a proposed biosimilar to Stelara®, in the United States of America.